Prostatic ductal adenocarcinoma showing Bcl-2 expression

Tulunay O., Orhan D., Baltaci S., Gogus Ç. M., Muftuoglu Y.

INTERNATIONAL JOURNAL OF UROLOGY, cilt.11, sa.9, ss.805-808, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 9
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1111/j.1442-2042.2004.00886.x
  • Dergi Adı: INTERNATIONAL JOURNAL OF UROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.805-808
  • Anahtar Kelimeler: Bcl-2, immunohistochemistry, p53, prostatic ductal carcinoma, urethral papillary carcinoma, CANCER
  • Ankara Üniversitesi Adresli: Evet

Özet

Prostatic ductal adenocarcinoma represents a rare histological variant of prostatic carcinoma with features of a papillary lesion at cystoscopy. There are conflicts regarding the existence, origin, staging, grading, treatment and clinical behavior of this tumor. The aim of the present study is to examine the expression of Bcl-2 and p53 in prostatic ductal adenocarcinoma and to evaluate its origin by analyzing prostate specific antigen, prostate specific acid phosphatase, cytokeratins, epithelial membrane antigen and carcinoembryonic antigen expressions. The results confirmed the expression of prostate specific antigen and prostate specific acid phosphatase in prostatic ductal adenocarcinoma. The demonstrated expression of Bcl-2 was predominant in the better-differentiated tumor. Bcl-2 expression appears not to be associated with neuroendocrine differentiation as assessed by chromogranin A reactivity. Thus, the first case of a prostatic ductal adenocarcinoma showing Bcl-2 expression is presented. The tumor was negative for p53.